Showing studies matching your search14 results shown

Studies (14 shown)

NCT07070232PHASE1, PHASE2RECRUITING

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor · BioNTech SECondition · Advanced Solid TumorIntervention · BNT326, PumitamigUpdated May 2026
NCT06712316PHASE2, PHASE3RECRUITING

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Sponsor · BioNTech SECondition · Non-small Cell Lung CancerIntervention · Pumitamig, PembrolizumabUpdated May 2026
NCT06827236PHASE1, PHASE2RECRUITING

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Sponsor · BioNTech SECondition · Locally Advanced Breast Cancer, Unresectable Breast CarcinomaIntervention · BNT323, BNT327Updated May 2026
NCT07255404PHASE2RECRUITING

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Sponsor · BioNTech SECondition · Pancreatic Ductal Adenocarcinoma (PDAC)Intervention · Pumitamig, Nab-paclitaxelUpdated Apr 2026
NCT07297212PHASE2RECRUITING

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Sponsor · BioNTech SECondition · Recurrent GlioblastomaIntervention · Pumitamig, BevacizumabUpdated Apr 2026
NCT06841055PHASE2RECRUITING

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Sponsor · BioNTech SECondition · Non-small Cell Lung CancerIntervention · Pumitamig, DocetaxelUpdated Apr 2026
NCT07147348PHASE1, PHASE2RECRUITING

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Sponsor · BioNTech SECondition · Advanced Solid TumorIntervention · BNT3212, PumitamigUpdated Apr 2026
NCT07492680PHASE2NOT_YET_RECRUITING

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor · Bristol-Myers SquibbCondition · Solid TumorsIntervention · BMS-986504, DaraxonrasibUpdated May 2026
NCT07221357PHASE2, PHASE3RECRUITING

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Sponsor · Bristol-Myers SquibbCondition · Untreated, Unresectable, or Metastatic Colorectal CancerIntervention · Pumitamig, FOLFOXUpdated May 2026
NCT07293351PHASE1, PHASE2RECRUITING

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Sponsor · Bristol-Myers SquibbCondition · Advanced Renal Cell Carcinoma (RCC)Intervention · Pumitamig, IpilimumabUpdated May 2026
NCT07173751PHASE3RECRUITING

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Sponsor · BioNTech SECondition · Breast NeoplasmsIntervention · Pumitamig, Nab-paclitaxel/PaclitaxelUpdated May 2026
NCT07221149PHASE2, PHASE3RECRUITING

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Sponsor · Bristol-Myers SquibbCondition · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaIntervention · Pumitamig, FolfoxUpdated May 2026
NCT06618287PHASE1, PHASE2RECRUITING

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Sponsor · Bristol-Myers SquibbCondition · Lung Cancer, Breast CancerIntervention · BMS-986507, OsimertinibUpdated May 2026
NCT06712355PHASE3RECRUITING

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor · BioNTech SECondition · Extensive-stage Small-cell Lung CancerIntervention · Pumitamig, AtezolizumabUpdated Feb 2026
Showing top 14 results. See all 14 results on CT.gov →